Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.42 USD | +0.23% | -2.29% | -19.24% |
Apr. 26 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
Apr. 26 | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
HSBC | |
Argus | |
Cantor Fitzgerald | |
BMO Capital | |
Leerink Partners | |
UBS | |
Goldman Sachs | |
Morgan Stanley | |
Wells Fargo Securities | |
Mizuho Securities | |
Truist Securities | |
RBC Capital Markets | |
Oppenheimer | |
Piper Sandler | |
TD Cowen | |
Barclays | |
Deutsche Bank Securities | |
BofA Securities | |
SVB Securities LLC | |
Cowen | |
Maxim | |
JPMorgan Chase | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
EPS Revisions
- Stock Market
- Equities
- GILD Stock
- Consensus Gilead Sciences, Inc.